PharmaIN Corporation and Shionogi & Co. have entered into a collaboration agreement with an exclusive two-year option to negotiate a license for the collaboration product.  

Shionogi Corp. will make an equity investment of up to $17M in PharmaIN in three transactions.

“We’ve enjoyed working with Shionogi since initial proof of concepts and are excited to expand our collaboration to advance novel, first in class therapy to benefit many millions of patients.  As a major research-driven pharmaceutical company Shionogi brings valuable experience, resources and innovation to our partnership,” said Elijah Bolotin, PhD, president and chief executive officer of PharmaIN Corp.

“Shionogi is very pleased to start this collaboration with PharmaIN, which has innovative platform technologies for drug discovery of various molecules including peptides, proteins and small molecules. We look forward to this collaboration that will surely bring us the great opportunity to provide many patients with innovative medicines,” said Takeshi Shiota, PhD, corporate officer, senior vice president, Pharmaceutical Research Division.